Cross A J, Crow T J, Ferrier I N, Johnson J A, Johnstone E C, Owen F, Owens D G, Poulter M
Psychopharmacology Suppl. 1985;2:104-10. doi: 10.1007/978-3-642-70140-5_13.
Neurochemical indices of dopaminergic function were assessed in basal ganglia of post-mortem brains of control subjects and schizophrenic patients who had been rated in life for the presence of movement disorder and neuroleptic intake. In schizophrenics who had been treated chronically with doses of neuroleptics, concentrations of dopamine D2 receptors were significantly increased above controls, whereas dopamine D1 receptors and dopamine metabolism were unchanged. Increased D2 receptors were also observed in basal ganglia of drug-free patients. Concentrations of dopamine D1 and D2 receptors in schizophrenics with movement disorder. Moreover, no relationship was found between dopamine receptor levels and the severity of movement disorder. Concentrations of the dopamine metabolite homovanillic acid were increased in the putamen and nucleus accumbens in a small number of patients with movement disorder compared with controls or patients without movement disorder. No changes were observed in markers of cholinergic and GABA-containing neurones. The present findings are not consistent with a "dopamine receptor hypersensitivity" concept of movement disorder in schizophrenia.
在对照受试者和精神分裂症患者的死后大脑基底神经节中评估了多巴胺能功能的神经化学指标,这些精神分裂症患者在生前已根据是否存在运动障碍和抗精神病药物摄入量进行了评级。在长期接受抗精神病药物治疗的精神分裂症患者中,多巴胺D2受体浓度显著高于对照组,而多巴胺D1受体和多巴胺代谢未发生变化。在未服用药物的患者的基底神经节中也观察到D2受体增加。有运动障碍的精神分裂症患者中多巴胺D1和D2受体的浓度。此外,未发现多巴胺受体水平与运动障碍严重程度之间存在关联。与对照组或无运动障碍的患者相比,少数有运动障碍的患者壳核和伏隔核中多巴胺代谢物高香草酸的浓度增加。在胆碱能神经元和含γ-氨基丁酸的神经元标记物中未观察到变化。目前的研究结果与精神分裂症运动障碍的“多巴胺受体超敏反应”概念不一致。